MORRISVILLE, N.C., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary diseases, ...

Gift 5 articles to anyone you choose each month when you subscribe. Bashing the Commonwealth Grants Commission’s formula for distributing the GST is a bipartisan sport in NSW. In 2018, the Coalition ...

Novartis AG (NYSE:NVS) is one of the Most Undervalued Growth Stocks to Buy According to Hedge Funds. On September 24, Novartis AG (NYSE:NVS) announced that new data on Kesimpta for relapsing multiple ...

Excel is the world’s most versatile data modeling tool—powering everything from household budgets to Fortune 500 profit and loss statements (P&Ls). Yet, the full power of Excel is available only to ...

Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, ...

KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced the acceptance of six abstracts for ePoster presentation at the 20 th German Allergy Congress taking place in Düsseldorf, Germany from ...

BSNL has introduced a new prepaid plan at Rs 485, catering to users looking for long-term validity and affordable benefits. The plan offers 2GB of daily high-speed data, unlimited local and STD calls, ...

REDMOND, Wash., Sept. 24, 2025 /PRNewswire/ -- SystImmune, Inc. (SystImmune), a clinical-stage biotechnology company, today announced the presentation of data on iza-bren (izalontamab brengitecan) and ...

Unlock access to every one of the hundreds of articles published daily on BroadwayWorld by logging in with one click. Ahead of his sold-out concert, SFJAZZ will host a rare open soundcheck experience ...

First PATHFINDER 2 Results Accepted as a Late-Breaking Presentation at the European Society for Medical Oncology (ESMO) Congress 2025; Results to be Submitted to FDA as Part of the Galleri Premarket ...

Longer-term data to be presented at the 5th International ATTR Amyloidosis Meeting for Patients and Doctors on September 25 highlighting up to three years of patient follow-up and additional insight ...